In case you missed Sachs Associates’ Annual Oncology Innovation Forum, be sure to watch the full panel discussion, “New Endpoints for Early-Stage Oncology Companies” featuring Nadim Ahmed, President and CEO. #Sachs_OIF
We are delighted to share the New Endpoints for Early-Stage Oncology Companies Panel from the 10th Annual Oncology Innovation Forum. Chaired by: Jeff Bockman, EVP Expert Advisor, Oncology, Lumanity Head, Oncology Center of Excellence, Lumanity Panellists: Colette Lipp, Director, Global BD Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany Jim Barlow, President & CEO, ImmunoGenesis, Inc. Matthew Price, Co-Founder, EVP & Chief Operating Officer, Promontory Therapeutics Inc. Nadim Ahmed, President & CEO, Cullinan Therapeutics, Inc. Raven Lin, Co-Founder & CEO, Pilatus Biosciences SA View here: https://lnkd.in/d8q8SAcz #OncologyEndpoints #EarlyStageOncology #CancerResearch #BiotechInnovation #Pharma #SachsForum #ASCO2024
Equipping organizations to leverage every drop of patient data for a patient-360 and enhanced outcomes
1moAwesome talk Nadim Ahmed, I love your commentary around "hope not being a strategy" in preclinical development and Cullinan's ruthless prioritization as you progress your pipelines.